DexCom Inc. (NASDAQ:DXCM) – Equities research analysts at B. Riley issued their Q3 2016 earnings per share estimates for shares of DexCom in a research note issued on Tuesday. B. Riley analyst G. Chodaczek anticipates that the firm will post earnings of ($0.15) per share for the quarter. B. Riley has a “Neutral” rating and a $97.00 price target on the stock. B. Riley also issued estimates for DexCom’s Q4 2016 earnings at $0.02 EPS, FY2016 earnings at ($0.61) EPS, Q1 2017 earnings at ($0.08) EPS, Q2 2017 earnings at $0.01 EPS, Q3 2017 earnings at $0.07 EPS, Q4 2017 earnings at $0.21 EPS and FY2017 earnings at $0.21 EPS.
DXCM has been the topic of a number of other reports. BTIG Research restated a “buy” rating and set a $92.00 price target on shares of DexCom in a research report on Tuesday, July 19th. Jefferies Group restated a “buy” rating and set a $98.00 price target (up from $90.00) on shares of DexCom in a research report on Friday, July 15th. Desjardins upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Friday, September 16th. Zacks Investment Research upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research report on Tuesday, July 19th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $93.00 price target on shares of DexCom in a research report on Friday, July 15th. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $95.08.
Shares of DexCom (NASDAQ:DXCM) traded down 3.32% during trading on Thursday, reaching $86.76. 1,427,066 shares of the company’s stock were exchanged. The stock’s market cap is $7.28 billion. The company has a 50 day moving average of $92.09 and a 200 day moving average of $76.85. DexCom has a 12-month low of $47.92 and a 12-month high of $96.38.
DexCom (NASDAQ:DXCM) last issued its earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.12. The company earned $137.30 million during the quarter, compared to the consensus estimate of $132.48 million. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. DexCom’s revenue was up 47.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.05) earnings per share.
Several large investors have recently added to or reduced their stakes in the stock. Bellwether Investment Group LLC bought a new stake in DexCom during the second quarter worth about $119,000. Bank of Montreal Can bought a new stake in DexCom during the second quarter worth about $134,000. CIBC Asset Management Inc bought a new stake in DexCom during the second quarter worth about $211,000. ProShare Advisors LLC bought a new stake in DexCom during the second quarter worth about $219,000. Finally, Suntrust Banks Inc. bought a new stake in DexCom during the second quarter worth about $230,000. 99.37% of the stock is currently owned by institutional investors and hedge funds.
In other news, insider Terrance H. Gregg sold 35,000 shares of the business’s stock in a transaction that occurred on Friday, August 5th. The shares were sold at an average price of $79.81, for a total value of $2,793,350.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Terrance H. Gregg sold 10,900 shares of the business’s stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $91.03, for a total transaction of $992,227.00. Following the completion of the sale, the insider now directly owns 451,486 shares in the company, valued at $41,098,770.58. The disclosure for this sale can be found here. 2.80% of the stock is currently owned by insiders.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.